Foss Halle E, Prebay Zachary J, Ebbott David, Buck Matthew B, Li Michael, Chung Paul H
Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Center for Digital Health and Data Science, Thomas Jefferson University, Philadelphia, PA, USA.
Transl Androl Urol. 2024 Aug 31;13(8):1537-1545. doi: 10.21037/tau-23-412. Epub 2024 Aug 26.
Over 25,000 men undergo inflatable penile prosthesis (IPP) placement yearly to treat erectile dysfunction (ED). Although various comorbidities are hypothesized risk factors for complications, this remains incompletely understood. Our objective was to utilize multi-institutional data to characterize risk for reintervention, complications, and infections in patients with common suspected risk factors undergoing IPP placement.
We queried the TriNetX database for adult men who underwent IPP placement from 2003-2023 utilizing Current Procedural Terminology (CPT) codes. We examined the impact of diabetes mellitus (DM), hypertension (HTN), nicotine use, radiation therapy (RT), radical prostatectomy (RP), and urethral surgery [urethroplasty, artificial urinary sphincter (AUS), male urethral sling (MS)] on clinical outcomes defined by International Classification of Diseases 10th Revision (ICD-10) codes. Our primary outcome was need for reintervention based on CPT codes. Secondary outcomes included overall rates of complication and infection utilizing ICD-10 codes. Analytics were performed using TriNetX to calculate risk ratios (RRs) and Kaplan-Meier (KM) survival. We evaluated outcomes overall and for each individual comparison cohort using the remaining demographic variables to perform propensity score matching (PSM).
In a total of 11,026 patients there was an overall 13.5% risk of undergoing at least one reintervention, with some undergoing multiple based on CPT codes. KM analysis showed a median IPP survival of 18.2 years and a projected 10- and 20-year survival probability at 70.6% and 48.4% respectively. Overall complication rate was 19.3% with a 5.2% rate of infection based on ICD codes. Patients with history of urethral surgery were at higher risk of both IPP complication and re-intervention. When further analyzing type of re-intervention, patients with a history of smoking, prior RP, and prior AUS/MS placement had higher rates of device removal. Patients with a history of diabetes were less likely to undergo IPP replacement at the time of explant. There were no identified risk factors for IPP infection.
This is the largest cohort of patients ever evaluated and can help guide patient selection and counseling. There was a higher rate of IPP complications than previously reported, but this may be due to different reporting parameters. History of prior urethral surgery conferred a higher risk of complications and re-intervention. These results can help guide patient selection and counseling.
每年有超过25000名男性接受可膨胀阴茎假体(IPP)植入手术以治疗勃起功能障碍(ED)。尽管各种合并症被认为是并发症的风险因素,但对此仍未完全了解。我们的目的是利用多机构数据来描述接受IPP植入手术且有常见疑似风险因素的患者再次干预、并发症和感染的风险。
我们使用当前手术操作术语(CPT)代码在TriNetX数据库中查询2003年至2023年期间接受IPP植入手术的成年男性。我们研究了糖尿病(DM)、高血压(HTN)、吸烟、放射治疗(RT)、根治性前列腺切除术(RP)和尿道手术[尿道成形术、人工尿道括约肌(AUS)、男性尿道吊带(MS)]对由国际疾病分类第10版(ICD - 10)代码定义的临床结局的影响。我们的主要结局是根据CPT代码确定的再次干预需求。次要结局包括使用ICD - 10代码计算的总体并发症和感染率。使用TriNetX进行分析以计算风险比(RRs)和Kaplan - Meier(KM)生存率。我们使用其余人口统计学变量进行倾向评分匹配(PSM),总体评估结局,并对每个单独的比较队列进行评估。
在总共11026名患者中,根据CPT代码,总体上有13.5%的风险至少接受一次再次干预,有些患者接受了多次再次干预。KM分析显示IPP的中位生存期为18.2年,预计10年和20年生存率分别为70.6%和48.4%。根据ICD代码,总体并发症发生率为19.3%,感染率为5.2%。有尿道手术史的患者发生IPP并发症和再次干预的风险更高。在进一步分析再次干预类型时,有吸烟史、既往RP史以及既往AUS/MS植入史的患者器械取出率更高。有糖尿病史的患者在取出假体时接受IPP置换的可能性较小。未发现IPP感染的风险因素。
这是有史以来评估的最大患者队列,有助于指导患者选择和咨询。IPP并发症发生率高于先前报道,但这可能是由于报告参数不同。既往尿道手术史会增加并发症和再次干预的风险。这些结果有助于指导患者选择和咨询。